# KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children

> **NCT02646839** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Michael Pulsipher** · enrollment: 50 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DEVICE:** CliniMacs TCR alpha-beta-Biotin system

## Key facts

- **NCT ID:** NCT02646839
- **Lead sponsor:** Michael Pulsipher
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2015-10
- **Primary completion:** 2025-11
- **Final completion:** 2025-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02646839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02646839, "KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02646839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*